Information

Information

NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of decitabine for the treatment of acute myeloid leukaemia. If, after doing this, organisations still wish to consider decitabine for the treatment of acute myeloid leukaemia, they should follow the advice set out in Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.

NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

Related NICE guidance

For information about NICE guidance that has been issued or is in development, see the NICE website.

  • National Institute for Health and Care Excellence (NICE)